IRWDIronwood Pharmaceuticals, Inc. - Class A — stock analysis & sentiment
Ironwood Pharmaceuticals, Inc. - Class A (IRWD) last closed at $4.53, in the upper half of its 52-week range of $1.26–$5.78. Composite market sentiment across 2 analyses is positive (+25 on a −100 to +100 scale), as of Sep 23, 2026.
Produced by the Synoptiv Research Engine from public financial data. Read the methodology.
Go beyond the overview
The thesis, technical signals, risk levels, and complete evidence — everything the overview leaves out.
What changed
Since the previous analysis (v1) on Aug 2, 2026.
IRWD rose to $4.53, from $4.23 at the previous analysis.
Composite sentiment ticked up from +18 to +25, still positive.
13 headlines since the last analysis — 13 neutral.
Market cap rose +1.57%, from $696.31M to $707.23M.
The written analysis on this page was refreshed for v2.
What the data says
An overview of the public data behind IRWD.
At $4.53, the stock sits in the upper portion of a 52-week band running from $1.26 to $5.78 — about 22% below the high and more than three times the low. A range that wide inside a single year describes a stock that has repriced substantially rather than one that has traded within a settled band.
The market capitalization of roughly $707 million works out to about 5.4 times trailing earnings and about 2.9 times forward earnings, so the market is paying a low multiple against both the earnings already reported and those currently projected. Behind that, the business converts about 33% of revenue to profit and grew revenue about 33% over the past year. Price-to-book reads as negative, which reflects a negative book value on the balance sheet rather than a usable valuation measure. A beta of 0.21 means the shares have historically moved with only a fraction of the broader market's swings, which places the source of that wide 52-week range with the company itself more than with the market around it.
The news flow divides fairly cleanly. The company-specific items are the substantive ones: a January 2026 piece on LINZESS net pricing, an April 2025 report of a sharp decline after the FDA requested an additional trial for a gastrointestinal drug, and 2024 coverage of a first-quarter report that came in below estimates. The rest are broad market roundups and screens in which the company appears as one name among several, or headlines about other companies entirely. The most recent item on the list is dated February 2026, so dedicated coverage has been thin in the months since.
Written from public market data. Research, not financial advice — the thesis, signals and risk levels are in the full report.
Price chart
IRWD daily price history.
Market sentiment
A composite of the public market data in this analysis, from −100 (bearish) to +100 (bullish).
This gauge blends news tone, analyst views, insider and congressional activity, and price momentum into a single score. The full report breaks down each driver and pairs it with the thesis.
See the full sentiment breakdown in the report →Key stats
A public snapshot of commonly used market and valuation measures.
Valuation & size
- Market cap
- $707.23M
- Enterprise value
- $1.07B
- P/E (TTM)
- 5.42
- Forward P/E
- 2.85
- Price / book
- -4.37
- Price / sales
- 1.82
Profitability & growth
- Net margin
- 33.36%
- Revenue growth
- +32.60%
- Earnings growth
- +1.26%
Price & risk
- Beta
- 0.21
- Average volume
- 2.24M
From noise to signal. The full report has IRWD’s thesis, trade signal, and risk levels.
About Ironwood Pharmaceuticals, Inc. - Class A
Ironwood Pharmaceuticals is a biotechnology company focused on treatments for gastrointestinal and rare diseases. Its commercial product is linaclotide, a guanylate cyclase type-C agonist sold as LINZESS in the United States and CONSTELLA in other markets, approved for adults with irritable bowel syndrome with constipation or chronic idiopathic constipation and for pediatric patients with functional constipation. Linaclotide is developed and commercialized through partnerships with AbbVie, AstraZeneca, and Astellas Pharma covering different territories. The company's pipeline includes apraglutide, a long-acting synthetic analog of glucagon-like peptide-2 studied in short bowel syndrome with intestinal failure in patients dependent on parenteral support, and in acute graft-versus-host disease; and IW-3300, another guanylate cyclase type-C agonist aimed at visceral pain conditions such as interstitial cystitis/bladder pain syndrome and endometriosis. Ironwood was incorporated in 1998 as Microbia and adopted its current name in 2008. It is headquartered in Boston, Massachusetts.
Latest news
Recent headlines related to IRWD, with vendor tone.
IRWD — frequently asked questions
Answered from the public data on this page.
What is the current market sentiment for IRWD?
As of Sep 23, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) carries positive (+25 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.
How has IRWD stock been performing?
Ironwood Pharmaceuticals, Inc. - Class A last closed at $4.53, in the upper half of its 52-week range of $1.26–$5.78.
What is IRWD's market cap and valuation?
Ironwood Pharmaceuticals, Inc. - Class A has a market capitalization of about $707.23M, a trailing P/E of 5.4.
What sector is IRWD in, and who are its competitors?
Ironwood Pharmaceuticals, Inc. - Class A operates in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic. Comparable companies include ANNX, CLYM, NVCT, MDXG, STTK.
Where can I find a full analysis of IRWD?
The full IRWD report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.
Analysis history
Every saved analysis, newest first.